New data from Novo Nordisk’s Phase IIIa ONWARDS 2 trial studying insulin icodec shows it is effective as a once-weekly treatment for Type 2 diabetes. Insulin icodec differs from other basal insulin products currently on the market, as they require once-daily injections. The trial reached its primary endpoint, with 37% of adults with type 2 diabetes who received the drug achieving an HbA1C less than 7% without having any indications of low blood sugar (hypoglycemia). This compared to 27% of patients receiving insulin degludec at 26 weeks.
On a Diabetes Treatment Satisfaction Questionnaire (DTSQ), participants indicated significantly greater satisfaction with the once-weekly insulin icodec compared to insulin degludec. In June, Novo Nordisk reported results from two Phase IIIa comparative trials showing insulin icodec was non-inferior to Sanofi’s insulin glargine, Lantus. The results of ONWARDS 1 demonstrated superiority over insulin glargine. ONWARDS 6 evaluated insulin icodec to Novo’s own Tresiba (insulin dugludec). This trial also hit its primary endpoint, demonstrating superiority over Tresiba.
Read more here
Don’t miss the next article from HealthFirst 100.
Join our mailing list to receive the latest posts from our blog directly in your inbox.